Pharma Marketing Network

Featured Conference Direct to Consumer Strategies for Medical Devices September 30 - October 1, 2004...

Off-label usage of drugs and medical devices accounts for a large percentage of profits yet also presents a minefield of potential legal, regulatory, ethical, and financial problems. To make matters worse, the regulatory and legal landscape has become more varied and confusing in recent years as organizations such as the DOJ, the OIG, and more have become involved. Here’s a chance for you to learn everything you need to know about this difficult topic in one easy stop.

An interactive forum to discuss how new technologies such as eDetailing and Tablet Ps allow companies to access more physicians and ultimately increase sales.  Learn how world-class pharmaceutical organizations are utilizing the capabilities of these technologies and overcoming the challenges of expanding sales forces and limited physician time.

The FDA just played the terrorist trump card in its battle against the legalization of the reimportation of drugs.

This article compares pharmaceutical prices paid by governments in the United States and Canada.

Multicultural communications can be a powerful addition to the armamentarium of the healthcare marketer.

Women account for more than half of the population in the United States and it makes absolute sense to market to women where, when, and how they choose.

Several drug re-importation bills are currently being considered in Congress.

Welcome to the latest issue of Pharma Marketing News. This is the Executive Summary version. You can download the full-text...

Dear Reader, Welcome to the September 2004 archive of Pharma Marketing News. Vol. 3, No....